Skip to main content
SNDX logo

SNDX · Syndax Pharmaceuticals Inc · Documents

Track SNDX — free
$8.72 -0.41 (-4.49%) At close · Nov 20 Play latest call Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20 2.18M Avg daily vol (3M) 2.61M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $172.35M up 627.8% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $83.3M up 81.6% 10-Q filed Nov 2, 2026 Latest results New CFO appointment effective November 9, 2026 8-K filed Nov 2, 2026 Earnings call Q2 2026 earnings call Held Aug 4, 2026
2026
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revuforj revenue rose 90%; MAXPIRe missed primary endpoint

Syndax reported third-quarter Revuforj net revenue of $60.7 million, up 90%, and Niktimvo net revenue of $67.4 million, up 47%. MAXPIRe missed its primary endpoint in IPF, and Syndax does not plan to move forward with further axatilimab development there.

Revenue $83.3M ▲ 81.6% Net loss $49.43M Diluted EPS -$0.55
Read from the MD&A section
4 source passages
Achieved $60.7 million in Revuforj net revenue in the third quarter of 2026, a 90% increase over the third quarter of 2025 and an 11% increase over the second quarter of 2026. Achieved $67.4 million in Niktimvo net revenue in the third quarter of 2026, a 47% increase over the third quarter of 2025 and an 12% increase over the second quarter of 2026. In October 2026, we announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis, or IPF, did not meet its primary endpoint of the annualized rate of decline in forced vital capacity or FVC. Based on the results observed, Syndax does not plan to move forward with further development of axatilimab in IPF. Open the document at this passage
Nov 2
Current report 8-K
New CFO appointment effective November 9, 2026

Syndax Pharmaceuticals appointed Aaron A. Ondrey CFO effective November 9, 2026, succeeding retiring Keith A. Goldan. Ondrey receives a $543,000 annual salary, 45% target bonus and option for 270,000 shares.

Financial results, Director or officer change, or executive pay Read from the first part of this long document
3 source passages
On November 2, 2026, the Company issued a press release announcing that Keith A. Goldan will retire as the Company’s Chief Financial Officer, principal accounting and financial officer and treasurer effective November 9, 2026, after which he will continue as an advisor for an interim period until his retirement. The Company also announced that Aaron A. Ondrey will join the Company as Chief Financial Officer, effective November 9, 2026. providing for the terms of his employment, including (i) an annual base salary of $543,000; (ii) an annual target bonus equal to 45% of his base salary; and (iii) a one-time grant of an option to purchase 270,000 shares of the Company’s common stock Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $72.79M ▲ 91.8% Net loss $49.36M Diluted EPS -$0.55
Jul 14
Current report 8-K
Other events AI summary on its way
Apr 30
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $64.86M ▲ 223.6% Net loss $42.67M Diluted EPS -$0.48
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $172.35M ▲ 627.8% Net loss $285.42M Diluted EPS -$3.29
2025
Mar 3
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $23.68M Net loss $318.76M Diluted EPS -$3.72
2024
Showing 1–50 of 154 documents
Key facts CIK 1395937 CUSIP 87164F105 13F (30d) 241 filings 222 filers Visit website Investor relations